PRA buys out Takeda JV, cements outpost in Japan

osaka japan
PRA's new subsidiary brings its total employees in Japan to 450. (Xavier Arnau/iStock)

Nearly three years after it first teamed up with Takeda Pharmaceutical, PRA Health Sciences has bought out its joint venture with the Japanese pharma. Previously known as the Takeda PRA Development Center, the unit was renamed PRA Health Sciences K.K. and is now operating in Japan as a subsidiary of PRA. 

The buyout closed June 1. The move will grow PRA’s staff in Japan to 450 “with opportunity for additional growth in the near term,” the CRO said in a statement last week. 

The duo struck their initial deal in September 2016, under which PRA would manage “an entire pipeline of studies” across all phases of clinical development for Takeda. It also agreed to provide regulatory, pharmacovigilance and other services for drugs in development as well as those already on the market. At the time, the partners expected to move about 300 Takeda employees over to PRA, which then took over pipeline development activities for Takeda in the U.S. and European markets. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: PRA Health Sciences makes $530M Symphony buy, reports 16% revenue growth in Q2

Five months later, PRA and Takeda expanded this arrangement to include Japan, gearing up to start their joint venture. PRA also bought out all the shares of Takeda Pharmaceutical Data Services. 

Takeda transferred about 140 Takeda employees to the new company “to support drug development and marketed products in Japan," said the company in a release announcing the expansion of the partnership. The joint venture closed in April that year. 

“In recent years, clinical development that bridges simultaneous global development has become a common practice. Through the wealth of experience and expertise in advanced clinical trials in Japan acquired through the joint venture, and our strengths in clinical development across 90 countries, we strive to become an ideal drug development partner for our clients on a global scale,” said PRA President and CEO Colin Shannon in the statement. 

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity.

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.